Allez Health Closes $60M Series A+ Financing to Advance CGM Biosensor Platform

Allez Health has closed a $60 million Series A+ financing led by Korean in-vitro diagnostics company Osang Healthcare, with participation from existing investors, to accelerate growth towards pivotal trials, support regulatory submissions and scale manufacturing operations.

Allez Health is a pioneering continuous glucose monitoring (CGM) biosensor platform with novel sensor technology and has achieved several significant milestones in patents, clinical trials and a pivotal study in 120 insulin users, and is expected to accelerate its progress towards commercialization in multiple global markets.

We are committed to bringing to market a sensor that combines access, affordability and reliable performance,” said Leif Bowman, co-founder and CEO of Allez Health. Allez Health’s innovative design and technical advances, coupled with Osang’s manufacturing capabilities and global reach, will provide meaningful access to world-class CGM technology for millions of people with diabetes,” said Dr Chulhun Kang, CEO of Osang Healthcare.


en_GBEnglish (UK)